Oct 23, 2024

chat

CDC ACIP Meeting: COVID-19, Influenza, RSV + Pneumococcal Vaccines | Oct. 23

Agenda (in Eastern Time)

  • 8:00am — Welcome and Introductions
  • 8:20am — Pneumococcal Vaccines
  • 10:30am — Break
  • 10:40am — Influenza Vaccines
  • 11:25am — Chikungunya Vaccines
  • 12:10pm — Break
  • 12:40pm — COVID-19 Vaccines
  • 3:35pm — Break
  • 3:45pm — Public Comment
  • 4:05pm — Voting (Pneumococcal, Influenza, COVID-19)
  • 4:35pm — RSV Vaccines
  • 5:30pm — Recess

CHD.TV offers a wide range of content pertaining to children's health. We regularly stream hearings, meetings and lectures from the World Economic Forum, National Institutes of Health, World Health Organization and other entities to keep you up to date the tactics and ideologies of those who influence public health, though Children's Health Defense may not have any affiliation with these organizations or individuals.

*The opinions expressed by the hosts and guests in this show are not necessarily the views of Children’s Health Defense.

DonateFree Signup

Resources

Pneumococcal Vaccines | Presentation Slides

Economic Analysis and Public Health Impact of PCV | Presentation Slides

Summary of three economic analyses on the use of PCV | Presentation Slides

Summary of Work Group Interpretation of EtR and Policy Options | Presentation Slides

Influenza Work Group—Introduction | Presentation Slides

2023–24 End of Season Influenza Vaccine Effectiveness – United States | Presentation Slides

Highly Pathogenic Avian Influenza A (H5N1) | Presentation Slides

CHIKUNGUNYA VACCINES | Presentation Slides

Update on chikungunya and chikungunya vaccines | Presentation Slides

CHIKV VLP vaccine Bavarian Nordic’s chikungunya vaccine candidate | Presentation Slides

Work Group interpretation of data for virus-like particle chikungunya vaccine | Presentation Slides

ACIP COVID-19 Vaccines Work Group | Presentation Slides

Implementation Considerations for Additional COVID-19 Vaccine Doses | Presentation Slides

COVID-19–Associated Hospitalizations Update — COVID-NET, July 2023–September 2024 | Presentation Slides

Effectiveness of COVID-19 vaccines | Presentation Slides

Economic analysis of an additional dose of the 2024-2025 COVID-19 vaccine | Presentation Slides

Evidence to Recommendations Framework: Additional Doses of 2024–2025 COVID-19 Vaccine in Older Adults and People with Moderate or Severe Immunocompromise | Presentation Slides

Clinical Considerations for the use of 2024-2025 COVID-19 Vaccines in the United States | Presentation Slides

Maternal/Pediatric Respiratory Syncytial Virus (RSV) Work Group | Presentation Slides

Clesrovimab (MK-1654): Pediatric Clinical Program | Presentation Slides

RSVpreF Vaccine, Preterm Birth, and Small for Gestational Age at Birth Preliminary Results from The Vaccine Safety Datalink | Presentation Slides

Maternal & Pediatric RSV Work Group Interpretations and Next Steps | Presentation Slides

Related Videos